This content is machine translated Uncontrolled type 2 diabetes Empagliflozin as an effective addition to triple therapies In patients with type 2 diabetes (T2D), a balanced glucose concentration is mainly achieved through drug therapies. If blood glucose control remains poor despite a triple combination of oral hypoglycaemic...…
View Post 12 min This content is machine translated Diabetic ketoacidosis Recommendations for action in practice Diabetic ketoacidosis (DKA) is an acutely life-threatening complication of diabetes mellitus that occurs predominantly in type 1 diabetes, but is also increasingly occurring in people with type 2 diabetes. A… CME-Test
View Post 5 min This content is machine translated Journal Club Nephrolithiasis and gout: SGLT2i could be an effective supplement Nephrolithiasis and gout are diseases with an increasing global burden and often co-occur with type 2 diabetes mellitus. SGLT2 inhibitors, which were first approved for the treatment of hyperglycemia in…
View Post 4 min This content is machine translated Pharmacotherapy for people over 80 A case of age discrimination? SGLT2 inhibitors and GLP1 receptor agonists have emerged as the drugs of first choice in the guidelines for type 2 diabetes. Sulfonylureas and insulin, on the other hand, were deprioritized…
View Post 5 min This content is machine translated Diabetic neuropathy and retinopathy How risky are SGLT2i and GLP1-RA? Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) play an important role in diabetes therapy. However, their effect on diabetic neuropathy and retinopathy is not clear.…
View Post 4 min This content is machine translated SGLT2i for heart failure HF prevalence in diabetes patients is underestimated in everyday clinical practice SGLT2 inhibitors can significantly reduce the risk of hospitalization for heart failure (HF) and death from cardiovascular causes in patients with diabetes and HF. However, the diagnosis of HF is…
View Post 4 min This content is machine translated Renal effects of empagliflozin Combination with semaglutide does not reduce albuminuria more than Empa mono SGLT2 inhibitors and GLP1 receptor agonists (GLP1-RA) are antidiabetic drugs with the potential to preserve kidney function. Their different mechanisms of action suggest that combination therapy could have additive or…
View Post 2 min This content is machine translated Chronic renal failure in nondiabetic patients Additive benefit of combination therapy with modern active substances The burden of complications of chronic kidney disease (CKD) can be reduced by giving patients RAAS inhibitors combined with SGLT2 inhibitors. This is shown by research recently published in the…
View Post 5 min This content is machine translated DGK 2018 Therapy of HFrEF: Something New, Old and Borrowed An update on modern heart failure therapy was given at the DGK Congress in Mannheim. Where are the ARNIs currently located? What is the procedure for special patient requests? There…
